After Piper Jaffray and Canaccord Genuity gave Biohaven Pharmaceutical Holding Co Ltd (NYSE: BHVN) a Buy rating last month, the company received another Buy, this time from Morgan Stanley. Analyst Matthew Harrison maintained a Buy rating on Biohaven Pharmaceutical Holding Co Ltd today and set a price target of $45. The company’s shares closed yesterday at $35.79.
According to TipRanks.com, Harrison is a 4-star analyst with an average return of 13.9% and a 61.7% success rate. Harrison covers the Healthcare sector, focusing on stocks such as Voyager Therapeutics Inc, Alexion Pharmaceuticals, and Rubius Therapeutics Inc.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Biohaven Pharmaceutical Holding Co Ltd with a $46.50 average price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $44.28 and a one-year low of $16.50. Currently, Biohaven Pharmaceutical Holding Co Ltd has an average volume of 330.6K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Biohaven Pharmaceutical Holding Co. Ltd. is a clinical-stage biopharmaceutical company, which engages in the research and development of late-stage product candidates targeting neurological diseases, including rare disorders.
